

CLAIMS

1. The use of a single botanical drug substance (BDS) or one or more botanical ingredients, obtained from a species of the genus *Scutellaria* selected from the group consisting of *Scutellaria baicalensis*, *S. amoena*, *S. barbata*, *S. discolor*, *S. hypericifolia*, *S. inbica*, *S. likiangensis*, *S. orthocalyx*, *S. rehderiana*, *S. scssiliflora* and *S. viscidula* in the manufacture of a medicament for the treatment of a patient with a SARS-CoV infection.
2. The use as claimed in claim 1 wherein the medicament is a total extract of a *Scutellaria* spp.
3. The use as claimed in claim 1 or 2 in which the medicament further comprises one or more excipients.
4. The use as claimed in any of the preceding claims wherein the botanical drug substance is a standardised extract.
5. The use as claimed in claim 4 wherein the botanical drug substance from the *Scutellaria* spp is standardised against a marker of baicalin and/ or baicalein.
6. The use as claimed in claims 4 or 5 wherein the standardised extract is a dried ethanolic extract.
7. The use as claimed in any of claims 4-6 wherein the standardised extract is a lyophilised extract.
8. The use as claimed in any of the preceding claims wherein the medicament is a botanical drug.
9. The use as claimed in claim 8 wherein the botanical drug is packaged in a sachet.

10. The use as claimed in claim 9 wherein the botanical drug is packaged with a dispensing container.

11. The use as claimed in claim 10 wherein the dispensing container has a sealable
5 lid.

12. The use as claimed in claim 3 wherein the excipients comprise one or more gellants or thickeners comprising at least one xanthum gum having a particle size distribution such that 100% by weight of the particles pass a 60 mesh sieve, 95% by
10 weight of the particles pass a 80 mesh sieve and 70% by weight of the particles pass a 200 mesh sieve; one or more fillers; and one or more wetting agents or surfactants.

13. The use as claimed in claim 1 wherein the one or more botanical ingredients obtained from a species of the genus *Scutellaria* are plant flavenoids or synthetic
15 equivalents thereof.

14. The use as claimed in claim 13 wherein the plant flavenoids is/are selected from the group consisting of baicalein, baicalin and wogonin.

15. The use of a botanical raw material (BRM), a botanical drug substance (BDS) or one or more botanical ingredients, obtainable from a species of the genus *Scutellaria* in the manufacture of an anti viral medicament.
20

16. The use as claimed in claim 15 wherein the antiviral medicament is for the
25 treatment of a patient with a positively stranded RNA viral infection.

17. The use as claimed in claim 15 or 16 wherein the medicament is for the treatment of a patient with a SARS-CoV infection.

18. A suspension dosage medicament comprising a *Scutellaria* spp.
30

19. The use of one or more botanical raw materials (BRM), one or more botanical drug substances (BDS), or one or more botanical ingredients obtainable from a species of the genus:

- a) *Scutellaria*;
- 5 b) *Lonicera*;
- c) *Forsythia*; or
- d) *Rabdosia*

in the manufacture of a botanical drug (BD), or dietary supplement for the treatment of SARS-CoV.

10

20. A suspension powder mixture comprising as botanicals

Forsythia in an amount by weight relative to the total weight of all the botanical raw materials of from 30 to 70 %,

15 *Lonicera* in an amount by weight relative to the total weight of all the botanical raw materials of from 12.5 to 37.5%, and

Scutellaria in an amount by weight relative to the total weight of all the botanical raw materials of from 12.5 to 37.5% and as excipients:

20 one or more gellants or thickeners comprising at least one xanthum gum having a particle size distribution such that 100% by weight of the particles pass a 60 mesh sieve, 95% by weight of the particles pass a 80 mesh sieve and 70% by weight of the particles pass a 200 mesh sieve; one or more fillers; and one or more wetting agents or surfactants.

21. A suspension powder mixture as claimed in claim 20 comprising standardised
25 extracts of each of the *Forsythia*, *Lonicera* and *Scutellaria* species.

22. A suspension powder mixture as claimed in claim 21 wherein:

 the *Forsythia spp* is standardised against a marker of Phillyrin;

30 the *Scutellaria spp* is standardised against a marker of either or both of Baicalin and Baicalein, and the

Lonicera spp is standardised against a marker of Chlorogenic acid and/ or caffeic acid.

23. The use of one or a plurality of of baicalin, baicalein, chlorogenic acid, forsythiaside, caffeic acid and phillyrin in the manufacture of a medicament for use in the treatment of SARS-CoV.

5 24. A medicament consisting essentially of botanical drug substances or botanical ingredients obtainable from a species of:

a) *Scutellaria*;

b) *Lonicera*;

c) *Forsythia*; and

10 d) *Rabdosia*

25. A method of treating SARS-Co V comprising administering to a patient a medicament as claimed in any of the preceding claims.